Clinical Research Directory
Browse clinical research sites, groups, and studies.
Modifying PEST for Psoriatic Arthritis Screening
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.
Official title: A Multicenter, Prospective, Study to Evaluate the Impact of Modifying the Validated Psoriasis Epidemiology Screening Tool (PEST) on the Potential Diagnosis of Psoriatic Arthritis in Adult Patients With Moderate-to-severe Plaque Psoriasis in Canada ("ScreenX")
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
502
Start Date
2025-01-23
Completion Date
2026-08-28
Last Updated
2026-02-17
Healthy Volunteers
Yes
Conditions
Interventions
PEST Screening group
PEST Screening group
Locations (15)
Novartis Investigative Site
Kelowna, British Columbia, Canada
Novartis Investigative Site
Surrey, British Columbia, Canada
Novartis Investigative Site
Fredericton, New Brunswick, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Hamilton, Ontario, Canada
Novartis Investigative Site
Markham, Ontario, Canada
Novartis Investigative Site
Richmond Hill, Ontario, Canada
Novartis Investigative Site
Stoney Creek, Ontario, Canada
Novartis Investigative Site
Waterloo, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Québec, Quebec, Canada
Novartis Investigative Site
Ste-Foy, Quebec, Canada
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada
Novartis Investigative Site
Saskatoon, Saskatchewan, Canada